Daxor (DXR) Stock Price, News & Analysis

Company Overview

Daxor Corporation (NASDAQ: DXR) is a medical device and biotechnology company focused on blood-volume measurement and related diagnostic applications. Its primary product is the BVA-100 Blood Volume Analyzer, a system designed to measure a patient’s total blood volume, plasma volume, red blood cell volume and hematocrit.

The BVA-100 uses a blood sample and an iodine-131-labeled albumin tracer to provide quantitative blood-volume measurements. The technology is intended to support clinical assessment and management in areas including heart failure, critical care, kidney disease, blood disorders and perioperative care, where accurate information about a patient’s fluid and blood-volume status can assist treatment decisions.

Daxor markets its technology primarily to hospitals and other healthcare providers and also supports clinical research involving blood-volume measurement. The company is headquartered in New York and has been publicly traded under the symbol DXR for several decades. Michael Feldschuh has served as the company’s chief executive officer.

Key Stats

• Today's Range: $8.42 to $8.75
• 50-Day Range: $8.45 to $11.72
• 52-Week Range: $8.40 to $14.76
• Volume: 8,312 shs
• Average Volume: 14,063 shs
• Market Capitalization: $49.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Moderate Buy

Company Calendar

• Today: 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:DXR
• Previous Symbol: NYSEAMERICAN:DXR
• CIK: 27367
• Web: www.daxor.com
• Phone: 212-244-0555
• Fax: 212-244-0806
• Employees: 37
• Year Founded: 1970

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $8.15 million
• Price / Sales: 6.05
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 5,838,000
• Free Float: 2,831,000
• Market Cap: $49.33 million
• Optionable: Not Optionable
• Beta: 0.43